Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mohammad Alkhalil

Showing results (1-10 of 146) with videos related to

Pageof 15
Sort By:
JAMA Cardiology|June 23, 2021
Myocardial Infarction and EvolocumabMohammad Alkhalil
Lancet (London, England)|March 15, 2018
Bioresorbable polymer drug-eluting stentsMohammad Alkhalil
Atherosclerosis|December 23, 2019
Effects of intensive lipid-lowering therapy on mortality after coronary bypass surgery: A meta-analysis of 7 randomised trialsMohammad Alkhalil
Journal of the American College of Cardiology|April 25, 2020
Complete Revascularization in STEMI, Early Clinical Benefits Are Still PlausibleMohammad Alkhalil
Current Cardiology Reviews|March 17, 2022
An Overview of Current Advances in Contemporary Percutaneous Coronary InterventionMohammad Alkhalil
JACC. Cardiovascular Interventions|December 8, 2018
Safety of the Deferral of Coronary Revascularization on the Basis of Instantaneous Wave-Free Ratio and Fractional Flow Reserve Measurements in Stable Coronary Artery Disease and Acute Coronary SyndromesMohammad Alkhalil
The New England Journal of Medicine|May 21, 2020
Lipoprotein(a) Reduction in Persons with Cardiovascular DiseaseMohammad Alkhalil
The New England Journal of Medicine|May 23, 2019
Alirocumab after Acute Coronary SyndromeMohammad Alkhalil
Current Cardiology Reviews|February 3, 2021
Novel Applications for Invasive and Non-invasive Tools in the Era of Contemporary Percutaneous Coronary RevascularisationMohammad Alkhalil
Circulation|July 11, 2018
Letter by Alkhalil Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)"Mohammad Alkhalil
Pageof 15

Showing results (1-10 of 146) with videos related to

Sort By:
Pageof 15
JAMA Cardiology|June 23, 2021
Myocardial Infarction and EvolocumabMohammad Alkhalil
Lancet (London, England)|March 15, 2018
Bioresorbable polymer drug-eluting stentsMohammad Alkhalil
Atherosclerosis|December 23, 2019
Effects of intensive lipid-lowering therapy on mortality after coronary bypass surgery: A meta-analysis of 7 randomised trialsMohammad Alkhalil
Journal of the American College of Cardiology|April 25, 2020
Complete Revascularization in STEMI, Early Clinical Benefits Are Still PlausibleMohammad Alkhalil
Current Cardiology Reviews|March 17, 2022
An Overview of Current Advances in Contemporary Percutaneous Coronary InterventionMohammad Alkhalil
JACC. Cardiovascular Interventions|December 8, 2018
Safety of the Deferral of Coronary Revascularization on the Basis of Instantaneous Wave-Free Ratio and Fractional Flow Reserve Measurements in Stable Coronary Artery Disease and Acute Coronary SyndromesMohammad Alkhalil
The New England Journal of Medicine|May 21, 2020
Lipoprotein(a) Reduction in Persons with Cardiovascular DiseaseMohammad Alkhalil
The New England Journal of Medicine|May 23, 2019
Alirocumab after Acute Coronary SyndromeMohammad Alkhalil
Current Cardiology Reviews|February 3, 2021
Novel Applications for Invasive and Non-invasive Tools in the Era of Contemporary Percutaneous Coronary RevascularisationMohammad Alkhalil
Circulation|July 11, 2018
Letter by Alkhalil Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)"Mohammad Alkhalil
Pageof 15